Uterine Cancer
![Neurocrine Biosciences, elagolix, hyperplasia, phase 3 trial data, FDA, uterine cancer, congenital adrenal hyperplasia](https://pharmtales.com/wp-content/uploads/2023/09/Neurocrine-advances-potential-blockbuster-drug-for-endometrial-hyperplasia-after-phase-3-success.jpg)
Neurocrine advances potential blockbuster drug for endometrial hyperplasia after phase 3 success
Anika Sharma
Neurocrine Biosciences is banking on its hyperplasia drug, crinecerfont, which analysts predict could be a blockbuster. The company has been ...